Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma

Table 1 Comparison of demographic and clinical data

Factor		Conforming to the criteria (n = 85)	Outside the criteria (n= 57)	P value
Age (yr)		65.0 ± 8.4	60.1 ± 12.7	0.007
Gender	Male	62 (73%)	44 (77%)	0.57
	Female	23 (27%)	13 (23%)
Child-Pugh score	Class A	71 (84%)	54 (95%)	0.04
	Class B	14 (16%)	3 (5%)
	Class C	0	0
Total bilirubin (mg/dL)		0.90 ± 0.55	0.74 ± 0.32	0.04
	< 1	42 (49%)	41 (72%)	0.008
	≥ 1	43 (51%)	16 (28%)
Albumin (g/dL)		3.7 ± 0.5	3.8 ± 0.50	0.04
	≤ 3.5	39 (46%)	14 (25%)	0.01
	>3.5	46 (54%)	43 (75%)
Prothrombin time (%)		83.0 ± 15.2	85.9 ± 17.6	0.30
	≤ 80	35 (41%)	25 (44%)	0.75
	> 80	50 (59%)	32 (56%)
Platelet count (× 104/mm3)		11.8 ± 6.3	17.5 ± 8.6	< 0.0001
	< 10	35 (41%)	13 (23%)	0.02
	≥ 10	50 (59%)	44 (77%)
ICG R15 (%)		19.8 ± 9.9	14.1 ± 1.2	0.0005
	< 15	26 (31%)	35 (61%)	0.0003
	≥ 15	59 (69%)	22 (39%)
Hepatitis virus	C positive	68 (80%)	26 (46%)	< 0.0001
	B positive	8 (10%)	15 (26%)	0.008
Tumor number	Single	77 (91%)	29 (51%)	< 0.0001
	Multiple	8 (9%)	28 (49%)
Tumor size (cm)		2.9 ± 1.2	7.6 ± 4.6	< 0.0001
	≤ 3	52 (61%)	5 (9%)	< 0.0001
	3-5	33 (39%)	11 (19%)
	> 5	0	41 (72%)
Histology	Well or moderately differentiated	68 (87%)	39 (71%)	0.02
	Poorly differentiated	10 (13%)	16 (29%)
Vascular invasion	Macroscopically positive	0	5 (8.8%)	0.005
	Microscopically positive	8 (10%)	18 (32%)	0.0008
TNM Staging by the LCSGJ1	I/II/III/IV-A	25/51/8/1	2/17/25/13	< 0.0001
	I+ II	76 (89%)	19 (33%)	< 0.0001
	III + IV-A	9 (11%)	38 (67%)
AFP (ng/mL)		933 ± 6610	31 473 ± 192 949	0.15
	AFP ≥ 20	52 (61%)	35 (61%)	0.98
	AFP ≥ 100	28 (33%)	26 (46%)	0.13
	AFP ≥ 200	16 (19%)	24 (42%)	0.003
	AFP ≥ 400	11 (13%)	23 (40 %)	0.0002
DCP (mAU/mL)		780 ± 4129	8168 ± 28 247	0.02
	DCP ≥ 40	45 (53%)	43 (75%)	0.007
	DCP ≥ 100	26 (31%)	36 (63%)	0.0001
	DCP ≥ 200	16 (19%)	30 (53%)	< 0.0001
	DCP ≥ 400	11 (13%)	27 (47%)	< 0.0001

¹Liver Cancer Study Group of Japan.